β¨ Medicines Distribution Consents
366 NEW ZEALAND GAZETTE No. 16
Schedule
| Name and Strength | Form | Name and Address of Manufacturer | Proprietary Name (if any) |
|---|---|---|---|
| Sodium monofluorophosphate | Toothpaste | Colgate-Palmolive Pty Limited, Labrador, Queensland, Australia | Colgate Sensation Whitening Fluoride Toothpaste plus Tartar |
| 0.75% w/w | |||
| Sodium fluoride 0.22% w/w | Toothpaste | Laboratorios Boniquet SA., Poligono Industrial Santiga, Barcelona, Spain | Yotuel |
Dated this 26th day of January 1999.
G. R. BOYD, Chief Advisor, Regulation and Safety, pursuant to delegation given by the Minister of Health on the 20th day of February 1997.
go758
Consent to the Distribution of Changed Medicines
Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the changed medicines which were referred to the Minister of Health under the provisions of section 24 (5) of the Act and are set out in the Schedule hereto:
Schedule
| Name and Strength | Form | Name and Address of Manufacturer | Proprietary Name (if any) |
|---|---|---|---|
| Quinapril hydrochloride | Tablets | Godecke AG, Freiburg, Germany and Parke Davis, Orleans Cedex, France | Accupril |
| equivalent to 5 mg, 10 mg, 20 mg quinapril | |||
| Hepatitis B virus vaccine | Injection, solution | SmithKline Beecham Biologicals Manufacturing, Rixensart, Belgium | Engerix-B |
| inactivated 10Β΅g in 0.5 mL, 20Β΅g in 1 mL | |||
| Saquinavir 200 mg | Capsule, soft gelatin | R P Scherer GmbH., Eberbach/Baden, Germany | Fortovase |
| Lenograstim 13.4MIU | Injection, powder | Chugai Pharmaceutical Co Limited, Utsunomiya, Tochigi, Japan | Granocyte 13 |
| Lenograstim 33.6MIU | Injection, powder | Chugai Pharmaceutical Co Limited, Utsunomiya, Tochigi, Japan | Granocyte 34 |
| Paclitaxel 6 mg/mL | Infusion, concentrate | Bristol-Caribbean Inc., Mayaguez, Puerto Rico | Taxol |
Dated this 31st day of January 1999.
G. R. BOYD, Chief Advisor, Regulation and Safety, pursuant to delegation given by the Minister of Health on the 20th day of February 1997.
go878
Renewal of Provisional Consent to the Distribution of a New Medicine
Pursuant to section 23 of the Medicines Act 1981, I provisionally consent to the sale, supply, or use in New Zealand of the new medicine (Clozaril) described in the Schedule hereto. This provisional consent has effect for 2 years from 4 February 1999.
This provisional consent is subject to the following conditions:
(i) Clozapine may only be prescribed by:
(a) medical practitioners who are vocationally registered under the Medical Practitioners Act 1995 in the branches of psychological medicine or psychiatry; and
(b) medical practitioners employed as registrars in psychological medicine or psychiatry who are under the supervision of persons of the kind referred to in paragraph (a) above.
(ii) Persons prescribing Clozapine must comply with the requirements of the New Zealand Guidelines for the use of Atypical Anti-Psychotic Drugs (2nd Edition September 1998) and the requirements of local Hospital and Health Service Protocols for use of Clozapine.
Schedule
| Name and Strength | Form | Name and Address of Manufacturer | Proprietary Name (if any) |
|---|---|---|---|
| Clozapine 25 mg, | Tablet | Novartis Pharma AG., Basle, Switzerland | Clozaril |
| 100 mg |
Dated at Wellington this 31st day of January 1999.
G. R. BOYD, Chief Advisor, Regulation and Safety, pursuant to delegation given by the Minister of Health on the 20th day of February 1997.
go877
Next Page →
PDF embedding disabled (Crown copyright)
View this page online at:
VUW Te Waharoa —
NZ Gazette 1999, No 16
NZLII —
NZ Gazette 1999, No 16
β¨ LLM interpretation of page content
π₯ Consent to the Distribution of a New Related Product
π₯ Health & Social Welfare26 January 1999
Medicines, Distribution, New Related Product, Toothpaste, Fluoride
- G. R. Boyd, Chief Advisor, Regulation and Safety
π₯ Consent to the Distribution of Changed Medicines
π₯ Health & Social Welfare31 January 1999
Medicines, Distribution, Changed Medicines, Tablets, Injection, Capsule, Infusion
- G. R. Boyd, Chief Advisor, Regulation and Safety
π₯ Renewal of Provisional Consent to the Distribution of a New Medicine
π₯ Health & Social Welfare31 January 1999
Medicines, Provisional Consent, Renewal, Clozapine, Tablet
- G. R. Boyd, Chief Advisor, Regulation and Safety